Logo

Apellis Expands its 2018 R&D Collaboration with Affilogic to Develop Nanofitins-Based Therapies for Neurological Diseases

Share this
Apellis Expands its 2018 R&D Collaboration with Affilogic to Develop Nanofitins-Based Therapies for Neurological Diseases

Apellis Expands its 2018 R&D Collaboration with Affilogic to Develop Nanofitins-Based Therapies for Neurological Diseases

Shots:

  • Affilogic receives research costs and will be eligible to receive development milestones along with royalty on net sales of any product. Apellis gets an exclusive, sublicensable, patent rights globally for all development project
  • The collaboration will combine Affilogic’s brain shuttle technology with Apellis’ deep expertise in complementing to develop of novel therapies for neurological diseases
  • The companies are working together to develop Nanofitin-based therapies that specifically target C3. In the next 12mos., Apellis anticipates submitting IND applications for research programs, including 2 pre-clinical products i.e., APL-1030 for neurodegenerative & other complement-driven diseases & APL-2006 for wet AMD and GA

Ref: GlobalNewswire | Image: Apellis

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions